Cost-effectiveness analysis of dupilumab among patients with uncontrolled severe asthma using LIBERTY ASTHMA QUEST Korean data

Table 2 Cost inputs

Parameter	Value in the base case	Value in DSA, lower/upper^a	PSA distribution used	Sources
Drug cost per cycle (USD)			Gamma	List price of dupilumab 200 mg/300 mg by HIRA
Dupilumab per the first cycle	1064	851/1277
Dupilumab per subsequent cycles	2129	1703/2555
Health states cost,^b per cycle (USD)			Gamma	Administrative medical database from the hospital
Controlled asthma	44	36/53
Uncontrolled asthma	106	85/128
Moderate exacerbation	191	152/229
Severe exacerbation – Office visit	141	113/169
Severe exacerbation – ED visit	300	240/360
Severe exacerbation – Hospitalization	4324	3460/5189

All costs are expressed in 2023 USD using an exchange rate of 1 USD to 1310 KRW
The model cycle length was 4 weeks
DSA Deterministic sensitivity analysis, ED Emergency department, HIRA Health Insurance Review and Assessment Service, KRW Korean Won, PSA Probabilistic sensitivity analysis, USD United Stated dollar
^aDrug costs and health states cost varied by ± 20%
^bThe costs for each health state consisted of expenditures on diagnosis, pharmacological treatments, and resources used for in-patient and out-patient services

ISSN: 2191-1991